Eli Lilly Signs AI Drug Deal With Insilico
Eli Lilly has reached a $2.75 billion deal with Hong Kong-based Insilico Medicine to commercialize drugs developed using generative AI, the companies announced Monday. The agreement includes $115 million upfront, milestone- and royalty-linked payments, and access for Insilico to Lilly's Gateway Labs; Insilico says it has developed 28 AI-enabled drugs, with nearly half in clinical stages.
Scoring Rationale
Major, well-documented licensing deal with material commercial value, limited by being a single partnership announcement.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalEli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global marketcnbc.com
- Read OriginalEli Lilly expands AI drug push with multibillion-dollar Insilico deal (LLY:NYSE)seekingalpha.com
